Comparative Pharmacology
Head-to-head clinical analysis: RAUVAL versus SERPIVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUVAL versus SERPIVITE.
RAUVAL vs SERPIVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
Selective serotonin reuptake inhibitor (SSRI); increases serotonin levels in the synaptic cleft by blocking reuptake via SERT inhibition.
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
1.5 mg/kg IV every 12 hours; maximum single dose 120 mg.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life 12 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Renal excretion unchanged 70%, biliary/fecal 25%, metabolic clearance 5%
Category C
Category C
Antihypertensive
Antihypertensive